跳至主要内容
临床试验/ACTRN12622001345774
ACTRN12622001345774招募中未知

Examining the clinical effectiveness of deep TMS treatment on depressive symptoms in adults with major depressive disorder (ACHIEVE)

Australian National University0 个研究点目标入组 240 人开始时间: 2022年10月19日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
入组人数
240

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 85 Years(—)
性别
All

入选标准

  • •Diagnosis of major depressive episode (MDE), in accordance with the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5), in the context of unipolar major depressive disorder or bipolar affective disorder.
  • •- 18-85 years of age.
  • •- Treatment resistant depression at Stage II of the Thase and Rush classification.
  • •- Hamilton Depression Rating Scale (HAMD) score of >17 (moderate – severe depression).
  • •- No increase or initiation of new antidepressant therapy in the four weeks prior to screening.
  • •- Demonstrated capacity to give informed consent.

排除标准

  • •- Inability to provide informed consent
  • •- Medically unstable patients
  • •- Concomitant neurological disorder or a history of a seizure disorder.
  • •- Patients who are pregnant or breastfeeding.
  • •- Active suicidal intent
  • •- Any psychotic disorder or current active psychotic symptoms
  • •-Patients who have intracranial implants deemed unsafe for TMS.
  • •- Significant difficulties understanding or communicating in English

研究者

相似试验